Spruce Biosciences Inc (SPRB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -38,966 | -53,036 | -47,919 | -46,180 | -42,292 |
| Depreciation Amortization | 21 | 46 | -566 | 90 | 189 |
| Accounts payable and accrued liabilities | -352 | -2,037 | 1,906 | -1,397 | -805 |
| Other Working Capital | -724 | -8,571 | 10,356 | 1,132 | 1,955 |
| Other Operating Activity | 6,694 | 7,634 | 2,948 | 4,672 | 5,076 |
| Operating Cash Flow | $-33,327 | $-55,964 | $-33,275 | $-41,683 | $-35,877 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | N/A | N/A | 55,784 | 23,700 | -79,075 |
| PPE Investments | N/A | N/A | -7 | -8 | -93 |
| Investing Cash Flow | $N/A | $N/A | $55,777 | $23,692 | $-79,168 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | N/A | N/A | 4,990 |
| Debt Repayment | -2,057 | -1,622 | -1,622 | N/A | -4,770 |
| Common Stock Issued | 50,070 | 246 | 53,794 | 78 | 462 |
| Other Financing Activity | -4,532 | -246 | -3,032 | -319 | -39 |
| Financing Cash Flow | $43,481 | $-1,622 | $49,140 | $-241 | $643 |
| Beginning Cash Position | 38,788 | 96,374 | 24,732 | 42,964 | 157,366 |
| End Cash Position | 48,942 | 38,788 | 96,374 | 24,732 | 42,964 |
| Net Cash Flow | $10,154 | $-57,586 | $71,642 | $-18,232 | $-114,402 |
| Free Cash Flow | |||||
| Operating Cash Flow | -33,327 | -55,964 | -33,275 | -41,683 | -35,877 |
| Capital Expenditure | N/A | N/A | -7 | -8 | -93 |
| Free Cash Flow | -33,327 | -55,964 | -33,282 | -41,691 | -35,970 |